Sentinel lymph node detection in early uterine cervical cáncer
DOI:
https://doi.org/10.31403/rpgo.v58i98Abstract
Objectives: To determine sentinel node (SN) detection feasibility and safety by using lymphatic mapping with 99m Tc dextran and injection of blue dye (patent blue) in patients with early cervical cáncer undergoing radical hysterectomy with bilateral pelvic lymphadenectomy. Design: Prospective study. Setting: Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru. Participants: Patients with early cervical cancer. Interventions: Between December 2003 and December 2006, 66 patients with early cervical cancer stages IA2 (n = 2), IB1 (n = 63) and IIA (n = 1) underwent sentinel lymph node detection with lymphoscintigraphy the day before operation and intraoperative lymphatic mapping with blue dye and gamma radiation detection probe. Surgical treatment was completed with radical hysterectomy and bilateral pelvic lymphadenectomy by laparotomy. Main outcome measures: Sentinel node detection. Results: One hundred and thirty-six sentinel nodes were detected in all 66 patients, average 2.06 per patient, by using the combined method 99m Tc dextran and patent blue. Most common location was the obturator region in 69.9% of cases (n = 95). Pelvic lymph node metastases were found by the sentinel node in 11 patients (sensitivity of 100%). In negative sentinel node cases (55 patients) no metastases were encountered (negative predictive value, NPV =100%). Conclusions: Sentinel node identification using 99m technetium dextran and blue dye injection is feasible and had a negative predictive value of 100%.
Downloads
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Disponible en: http://globocan.iarc.fr
Centro de Investigación Maes Heller, Instituto de Enfermedades Neoplásicas. Registro de Cáncer en Lima Metropolitana 1994 -1997. Lima: Instituto de Enfermedades Neoplásicas; 2004.
Registro de cáncer hospitalarioregión de salud Arequipa. Arequipa: 2002:1-74.
Albújar PF. El cáncer en Trujillo, 1996 - 2002: incidencia y mortalidad. Registro de Cáncer de Base Poblacional de Trujillo, Perú. Informe N° 4 Trujillo, Noviembre 2006.
Committee on Practice Bulletins – Gynecology. ACOG Practice Bulletin. Diagnosis and treatment of cervical carcinomas, num 35, May 2002. Obstet Gynecol. 2002;99(5 Pt 1):855–67.
Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC. Carcinoma of the cérvix treated with radiation therapy: I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer. 1991;67(11):2776–85.
Ho CM, Chien TY, Huang SH, Wu CJ, Shih BY, Chang SC. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecol Oncol. 2004;93 (2):458–64.
Takeda N, Sakuragi N, Takeda M, Okamoto K, Kuwabara M, Negishi H, et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand. 2002;81(12):1144–51.
Benedetti P, Basile S, Angioli R. Pelvic and aortic lymphadenectomy in cervical cancer: The standardization of surgical procedure and its clinical impact. Gynecol Oncol. 2009;113(2):284–90.
Sakuragi N. Up-to-date management of lymph node metástasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol. 2007;12:165–75.
Valdivia FH, Santos OC, Álvarez LM, Velarde NC, Mariátegui SJ, Galdos KO. Evaluación de factores pronósticos en pacientes tratadas con histerectomía radical tipos II y III para cáncer de cérvix en el Instituto Especializado de Enfermedades Neoplásicas de Perú. Boletín del Inen, Lima Perú. 2005;27(1):18-29.
Matsuura Y, Kawagoe T, Toki N, Tanaka M, Kashimura M. Longstanding complications after treatment for cancer of the uterine cervix - clinical significance of medical examinations at 5 years after treatment. Int J Gynecol Cancer. 2006;16(1):294-7.
Nieweg OE, Tanis PJ, Kroon BBR. The definition of a sentinel node. An Surg Oncol. 2001;8(6):538-41.
Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med. 1998;339:941–6.
Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, et al. Sentinel- node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349:1864-7.
Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392-9.
Morton DL. Sentinel node mapping and an International Sentinel Node Society: Current issues and future directions. Ann Surg Oncol. 2004(11):137-43.
Levenback C, Burke TW, Morris M, Malpica A, Lucas KR, Gershenson DM. Potential applications of intraoperative lymphatic mapping in vulvar cancer. Gynecol Oncol. 1995;59:216-20.
Mariani G, Moresco L, Viale G, Villa G, Bagnasco M, Canavese G, Buscombe J, Strauss W, Paganelli G. Radioguided sentinel node biopsy in breast cancer surgery. J Nuclear Med. 2001;42:1198-215.
Terada KY, Coel MN, Ko P, Wong JH. Combined use of intraoperative lymphatic mapping and lymphoscintigraphy in the management of squamous cell cancer of the vulva. Gynecol Oncol. 1998;70:65–9.
Cady B. Sentinel lymph node procedure in squamous cell carcinoma of the vulva. J Clin Oncol. 2000;18:2795–7.
Levenback C. Intraoperative lymphatic mapping and sentinel node identification: gynecologic applications. En: Schlag PM, Veronesi U, eds. Lymphatic Metastasis and Sentinel Lymphonodectomy. Berlin, Germany: Springer Verlag; 2000:150–60.
23. Maaike HM, Hedwig P, van de Nieuwenhof JA. The role of sentinel node biopsy in gynecological cancer: a review. Curr Op Oncol. 2009;21:425–32.
Schneider A. The sentinel concept in patients with cervical cancer. J Surg Oncol. 2007;96:337–41
Gortzak-Uzan L, Jimenez W, Nofech-Mozes S, Ismiil N, Khalifa MA, et al. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard? Gynecol Oncol. 2010;116:28-32.
Dargent D, Martin X, Mathevet P. Laparoscopic assessment of the sentinel lymph node in early stage cervical cancer. Gynecol Oncol. 2000;79:411-5.
Yuan S, Liang L, Liu J, Zhang HZ, Xiong Y, Yan XJ, Wei M, Zhang CQ. Sentinel lymph node identification with methylene blue in cervical cancer. Ai Zheng. 2004;23:1089-92.
Altgassen C, Hertel H, Brandstadt A, Kohler C, Durst M, Schneider A. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol. 2008;26:2943-51.
El-Ghobashy AE, Saidi SA. Sentinel lymph node sampling in gynaecological cancers: techniques and clinical applications. Eur J Surg Oncol. 2009;35:675–85.
Levenback C. Update on sentinel lymph node biopsy in gynecologic cancers. Gynecol Oncol. 2008;111:S42–S43. 31. Simmons R, Thevarajah S, Brennan MB , Christos P, Osborne M. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol. 2003;10(3):242–7.
Martínez-Palones JM, Gil-Moreno A, Pérez-Benavente M, Roca I, Xercavins J. Intraoperative sentinel node identification in early stage cervical cancer using a combination of radiolabeled albumin injection and isosulfan blue dye injection. Gynecol Oncol. 2004;92:845–50.
Kara PP, Ayhan A, Caner B, Gültekin M, Ugur O, Bozkurt MF, Usubutun A. Sentinel lymph node detection in early stage cervical cancer: a prospective study comparing preoperative lymphoscintigraphy, intraoperative gammaprobe, and blue dye. Ann Nucl Med. 2008;22(6):487–94.
van de Lande J, Torrenga B, Raijmakers PG, Hoekstra OS, van Baal MW, et al. Sentinel lymph node detection in early stage uterine cérvix carcinoma: a systematic review. Gynecol Oncol. 2007;106(3):604–13.
O’Boyle JD, Coleman RL, Bernstein SG, Lifshitz S, Muller CY, Miller DS. Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: a pilot study. Gynecol Oncol. 2000;79:238-43
Popa I, Plante M, Renaud MC, Roy M, Têtu B. Negative sentinel lymph node accurately predicts negative status of pelvic lymph nodes in uterine cervix carcinoma. Gynecol Oncol. 2006;103(2):649–53.
Oawa S, Kobayashi H, Amada S, Yahata S. Sonoda K, Kaku T, Wake N. Sentinel node detection with 99mTc phytate alone is satisfactory for cervical cancer patients undergoing radical hysterectomy and pelvic lymphadenectomy. Int J Clin Oncol. 2010;15(1):52–58}
Downloads
Published
How to Cite
Issue
Section
License
Esta revista provee acceso libre inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al publico, lo cual fomenta un mayor intercambio de conocimiento global.
